ALFA Finder| Margins | EBITDA margins improved YoY from 38.1% to 39.6%. |
|---|---|
| Demand visibility | Strong, with scheduled deliveries concentrated in H2 FY27. |
| Management confidence | High; citing strong underlying demand and historical alignment. |
Growth
Revenue fell 22.6% YoY to ₹4,182 Mn; PAT decreased 11.7% YoY to ₹1,199 Mn.
Outlook
Positioned to capture momentum in H2; maintenance of industry-leading margin profile via cost efficiencies.
Risks
Timing shifts in deliveries to key customers impacted Q1 performance; dependency on second-half concentration.
Last quarter's promises, checked
Delivered
- Guided 20% historical growth → delivered 18% FY26 revenue growth (= BEAT)
- Guided 30% EBITDA growth → delivered 31% FY26 EBITDA growth (= BEAT)
- Guided 30% PAT growth → delivered 31% FY26 PAT growth (= BEAT)
Partly delivered
- Guided 38-40% EBITDA margins → delivered 39.6% in Q1FY27 (= PARTIAL)
Missed
- Guided Q1FY27 momentum → delivered -22.6% YoY revenue growth (= MISS)
Investor Presentation filed with NSE, NSE: ANTHEM. Summary written with AI assistance from the document.
Anthem Biosciences Ltd: key numbers
- Share price
- ₹951.15
- Market cap
- ₹53,568 Cr
- Revenue (annual)
- ₹2,124 Cr
- Net profit (annual)
- ₹591.8 Cr
- P/E (TTM)
- 87.2×Sector 43.8×
- Promoter holding
- 71.40%-0.02% QoQ
- FII holding
- 3.79%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Anthem Biosciences Ltd
All →Anthem Biosciences Earnings Call Transcript: Key Takeaways
Anthem delivered robust Q2 results driven by CRDMO business and sharp margin expansion. Management highlighted strong operating leverage and cost discipline while scaling capacity.
- Call
- Guides 10% growth
Anthem Biosciences Investor Presentation: Key Takeaways
Q2FY27 revenue ₹5,940 Mn (+7.9% YoY), PAT ₹2,115 Mn (+21.9%), EBITDA margin 50.6% including ₹589 Mn other income. H1FY27 revenue fell 7.2%.
Anthem Biosciences Results Update
Anthem Biosciences reported Q2 FY27 consolidated revenue of ₹5,940 Mn, up 7.9% year-on-year, and PAT of ₹2,115 Mn. H1 FY27 PAT rose 7.2% to ₹3,314 Mn.
Anthem Biosciences Q2 FY27 Results: Net Profit ₹211.5 Cr, Up 22.0% YoY
Anthem Biosciences Ltd reported revenue from operations of ₹594 Cr (+7.9% YoY) and net profit of ₹211.5 Cr (+22.0% YoY) for Q2 FY27.
- Key figure
- Net profit ₹211.5 Cr · +22.0% YoY
Anthem Biosciences Board Meeting Date
Anthem Biosciences scheduled a Board meeting for November 3, 2026 to approve Q1 and H1 FY27 financial results. The trading window remains closed until November 5, 2026.
Anthem Biosciences Other Announcement
Anthem Biosciences Ltd has submitted its quarterly shareholding pattern as per SEBI regulations. The filing provides the current distribution of promoter and public shareholdings.